Tuesday, October 09, 2018 5:41:07 PM
http://www.guidedinc.com/publications/
and their "About Us" page says this:
This all sounds like Safe Harbor BS to me. Where is the proof of efficacy? If this tech is efficacious for other cancers, why have they spent 20 years focusing on Cervical Cancer alone?
The HPV vaccine is very definitely "a determining factor whether this company becomes viable." It's much cheaper overall to administer a vaccine than to detect cervical cancer in women who can't afford to pay for treatment when cancer is detected.
"Vaccine penetration will be negligible especially in places like India and more in less developed countries" sounds like BS to me. Forgive the unintended pun, but Luviva Scan penetration will be FAR more negligible than HPV vaccination in places like India and in less developed countries.
Governments in Asia and Africa are simply not going to pay for enough LuViva Scans to make this company viable. If they do anything large-scale, which is debatable considering the low social status of women on these continents, they will pay for vaccinations.
Finally, regarding the statement "Pap smear testing is in the tens of billions in the U.S. by 5 big pharmas, even with Gardisil" -- Yes, the USA is a different matter. Perhaps insurance in the USA would pay for LuViva Scans. There's a problem though -- this company has placed FDA clearance on the burner located BEHIND the back burner. They haven't done ANYTHING to further FDA clearance since the third FDA rejection back in 2014.
I don't know the reason for this delay -- say it's Big Pharma interference, say it's mismanagement, say the toxic lenders are trying to starve the company into BK.... Whatever excuse we want to make, FDA clearance was, is, and always will be this company's only hope for profitability.
Recent GTHP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 06:36:25 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/20/2024 06:42:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 06:48:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 04:24:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:28:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2023 09:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2023 04:44:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/07/2023 07:53:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 07:00:31 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM